Latest On Artelo Biosciences, Inc (ARTL):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 16:54 EST | News | Artelo Biosciences GAAP EPS of -$0.76 | N/A |  |
| 2023-03-31 17:24 EST | News | Artelo Biosciences GAAP EPS of -$3.56 | N/A | |
| 2023-01-25 00:55 EST | News | FDA issues final guidance on cannabis-based drugs for developers | N/A | |
| 2022-11-09 02:35 EST | News | Artelo Biosciences GAAP EPS of -$0.82 beats by $0.09 | N/A | |
| 2022-08-16 21:33 EST | News | Artelo jumps 21% as publication highlights pre-clinical data on drug platform | N/A | |
About Artelo Biosciences, Inc (ARTL):
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences has research collaboration with Trinity College Dublin to Investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, read more...Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.
General
- Name Artelo Biosciences, Inc
- Symbol ARTL
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 3
- Fiscal Year EndAugust
- IPO Date2017-11-14
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Web URLhttp://www.artelobio.com
Valuation
- Price/Book (Most Recent Quarter) 3.19
- Enterprise Value EBITDA 0.04
Financials
- Most Recent Quarter 2020-11-30
- Current Year EPS Estimate -$0.46
- Next Year EPS Estimate -$0.40
- Return on Assets -40%
- Return on Equity -68%
- Earnings Per Share -$1.08
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 30.64 million
- EBITDA -2945807
- Analyst Target Price $6
- Book Value Per Share $0.60
Share Statistics
- Shares Outstanding 15.71 million
- Shares Float 12.42 million
- % Held by Insiders 782%
- % Held by Institutions 28.85%
- Shares Short 2.85 million
- Shares Short Prior Month 2.84 million
- Short Ratio 0.14
- Short % of Float 19%
- Short % of Shares Outstanding 18%
Technicals
- Beta 1.53
- 52 Week High $3.67
- 52 Week Low $0.45
- 50 Day Moving Average 1.81
- 200 Day Moving Average 1.01
Dividends
- Dividend Date 2019-06-21
- ExDividend Date N/A
- Dividend Yield 0%
Artelo Biosciences, Inc (ARTL) Dividend Calendar:
ARTL's last dividend payment was made to shareholders on June 21, 2019.
Artelo Biosciences, Inc (ARTL) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Artelo Biosciences, Inc (ARTL) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Artelo Biosciences, Inc (ARTL) Chart:
Artelo Biosciences, Inc (ARTL) News:
Below you will find a list of latest news for Artelo Biosciences, Inc (ARTL) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Artelo Biosciences, Inc (ARTL) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Artelo Biosciences, Inc (ARTL) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-04 | 10-K (Annual report [Section 13 and 15(d), not S-K Item 405]) | |
| 2020-10-28 | PRE 14A (Other preliminary proxy statements) | |
| 2020-10-26 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-10-22 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-10-19 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-10-19 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-10-15 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-10-15 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-10-15 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-10-14 | 8-K (Current report) | |
| 2020-10-13 | 424B4 (Prospectus [Rule 424(b)(4)]) | |
| 2020-10-09 | S-1MEF (Registration adding securities to prior Form S-1 registration [Rule 462(b)]) | |
| 2020-10-08 | S-1/A (General form for registration of securities under the Securities Act of 1933) | |
| 2020-10-08 | EFFECT (Notice of Effectiveness) | |
| 2020-10-07 | S-1/A (General form for registration of securities under the Securities Act of 1933) | |
| 2020-10-07 | CORRESP (Correspondence) | |
| 2020-10-07 | CORRESP (Correspondence) | |
| 2020-10-06 | S-1/A (General form for registration of securities under the Securities Act of 1933) | |
| 2020-10-06 | FWP (Filing under Securities Act Rules 163/433 of free writing prospectuses) | |
| 2020-10-02 | UPLOAD (SEC-generated letter) | |
Artelo Biosciences, Inc (ARTL) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Artelo Biosciences, Inc (ARTL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 782%
Institutional Ownership: 2885%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-05-15-05:00 | Gregory D. Gorgas | Pres, CEO, CFO, Treas & Secr | Buy | 4,200.00 | 1.21 | 5,071.92 | 262,176.00 | |
| 2020-05-04-05:00 | Gregory D. Gorgas | Pres, CEO, CFO, Treas & Secr | Buy | 4,167.00 | 1.20 | 5,000.40 | 257,976.00 | |
| 2020-05-04-05:00 | CONNIE MATSUI | Director | Buy | 41,667.00 | 1.20 | 50,000.40 | 56,667.00 | |
| 2009-11-18 | BRIAN SCHLIER | Vice President | Sell | 15,000.00 | 0.00 | | ||
| 2009-11-18 | DEAN T JOHNSON | Senior Vice President & C.F.O. | Sell | 20,000.00 | 0.00 | | ||
| 2009-11-18 | DONALD T NETTER | Director | Sell | 1,000.00 | 0.00 | | ||
| 2009-11-18 | H WILLIAM SMITH | V. P., Gen Counsel & Secretary | Sell | 10,000.00 | 0.00 | | ||
| 2009-11-18 | JAMES G TATUM | Director | Sell | 9,429.00 | 0.00 | | ||
| 2009-11-18 | John A Whritner | Director | Sell | 3,400.00 | 0.00 | | ||
| 2009-11-18 | JOHN L LAHEY | Director | Sell | 3,898.00 | 0.00 | | ||
| 2009-11-18 | LRTA, INC. | 10% Share Holder | Sell | 16,279,971.00 | 0.00 | | ||
| 2009-11-18 | STEVEN B LAPIN | President & C.O.O. | Sell | 195,665.00 | 0.00 | | ||
| 2009-11-18 | W PHILLIP NIEMEYER | Executive Vice President | Sell | 60,000.00 | 0.00 | | ||
| 2009-11-18 | CORP /DE/ GENEVE | 10% Share Holder | Buy | 1,000.00 | 1,000.00 | | ||
| 2009-11-18 | CORP /DE/ GENEVE | 10% Share Holder | Buy | 13.00 | 13.00 | | ||
| 2009-11-18 | CORP /DE/ GENEVE | 10% Share Holder | Buy | 65.00 | 65.00 | | ||
| 2009-11-18 | CORP /DE/ GENEVE | 10% Share Holder | Buy | 922.00 | 922.00 | | ||
| 2009-06-05 | W PHILLIP NIEMEYER | Executive Vice President | Buy | 338.00 | 7.77 | 2,626.26 | 16,400.00 | |
| 2009-06-03 | W PHILLIP NIEMEYER | Executive Vice President | Buy | 100.00 | 7.79 | 779.00 | 16,062.00 | |
| 2009-05-29 | W PHILLIP NIEMEYER | Executive Vice President | Buy | 562.00 | 7.76 | 4,361.12 | 15,962.00 | |